Percutaneous aortic valve replacement: Which patients are suitable for it? A quest for a controlled use  by di Marco, Francesca & Gerosa, Gino
P
s
F
Editorials di Marco and Gerosa
2
ED
ITO
RIA
Lercutaneous aortic valve replacement: Which patients are
uitable for it? A quest for a controlled use
rancesca di Marco, MD, and Gino Gerosa, MD
T
t
t
r
r
s
i
t
r
a
p
c
w
q
t
s
t
s
t
t
f
r
t
s
s
a
u
m
w
eFrom the Department of Cardiac, Thoracic,
and Vascular Sciences, Padua University
Medical School, Division of Cardiac Sur-
gery, Padova, Italy.
Received for publication July 25, 2006; ac-
cepted for publication Aug 8, 2006.
Address for reprints: Gino Gerosa, MD,
Division of Cardiac Surgery, Department of
Cardiac, Thoracic, and Vascular Sciences,
Padua University Medical School, Via Gi-
ustiniani 2, 35100 Padova, Italy (E-mail:
gino.gerosa@unipd.it).
J Thorac Cardiovasc Surg 2007;133:294-8
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgery
See related editorial on page
299.i
doi:10.1016/j.jtcvs.2006.08.074
94 The Journal of Thoracic and Cardiohe internal thoracic artery–to–left descending coronary artery bypass graft
(CABG) is recognized as the gold standard therapy for coronary artery
disease. Nevertheless, percutaneous revascularization is currently adopted as
he first-line approach, not only in the treatment of multivessel disease but even in
he presence of left main stenosis and in patients with diabetes. Although no major
andomized trials justify this policy, still it has been currently adopted.1 Many
easons might explain the widespread embracement of endovascular techniques over
urgery. In one word: simplification. The patient does not need to be sedated or
ntubated. The duration of the procedure is relatively short, and the results can be ex
empore visualized, allowing a possible adjustment. A very short hospitalization is
equired for recovery, and the patient’s stress is minimized. Finally, the procedures
re easily repeatable, in contrast to the widely known risks of a resternotomy.
Just because of their simplified character, a wide number of interventional
rocedures are performed every day compared with cardiac operations, allowing the
atheter technology to evolve rapidly: new techniques are launched on the market
ith an impressive speed and are applied in the catheterization laboratories with a
uick turnover. By contrast, apart from spare attempts (ministernotomy, port-access
echnique, robotics), cardiac surgery techniques remain substantially unchanged
ince their introduction.
Valve surgery has long represented a stronghold for the cardiac surgeon, but
hings might change. In fact, although the research on the ideal valve substitute is
till ongoing, endovascular techniques have recently been proposed as alternative
herapies for both mitral and aortic disease. The attempt to renew valve surgery with
he introduction of robotics for mitral valve surgery has actually complicated it. In
act, even if robotic surgery can minimize patient trauma and promote a faster
ecovery, it is associated with higher use of resources, in both economic and human
erms. Even if surgery can be realized without opening the chest, robotics is not
ynonymous with simplification, whereas a percutaneous technique remains a
implified technique when compared with surgery.
The opportunity to replace an aortic valve in the awake patient by a vascular
ccess is undoubtedly appealing both for the patient and the physician, but before an
ncontrolled diffusion of endovascular aortic valve replacement (AVR) occurs,
imicking the widespread preference for percutaneous revascularization over CABG,
e should ask ourselves these questions:
1. What are the current results of surgical AVR in terms of in-hospital morbidity
and mortality?
2. Is percutaneous AVR effective?
3. Are we sure that the risks related to valve surgery are greater than the risks
of an endovascular procedure? In fact, simple does not necessarily mean safe
and durable; on the other hand, surgery does not necessarily imply a signif-
icant risk.
4. The clinical application of percutaneous AVR has started on patients ex-
cluded from cardiac surgery; currently, which patients would be excluded
from surgery after due consideration and why?
The analysis of The Society of Thoracic Surgeons National Cardiac Database
videnced that, among 46,397 patients, mortality for AVR ranges from 4.3% for first
solated AVR to 25% for redo surgery or multiple valve replacement plus CABG,
vascular Surgery ● February 2007
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Lith an overall rate of 6.4%.2 In a very impartial editorial,
ish3 outlines that the surgical results are excellent even in
igh-risk patients and, for this reason, percutaneous ap-
roaches must (1) justify their adoption and (2) guarantee
igh standards for performance.
Nevertheless, in minor and tendentious reports,4 surgical
ortality is considered prohibitive in certain categories of
atients, which are vaguely described as “ at high risk,” and
lternative solutions (interventional, of course) are “needed.”
n the contrary, we believe that the adoption of percutaneous
pproaches, even in selected cases, needs to be justified.
According to the current results of surgical AVR at our
nstitution between December 2002 and June 2006, 341
onsecutive patients (mean age 70  11 years, median age
3 years, range 23–89 years) underwent isolated AVR.
ifty-three (15%) patients were 80 years old or older, and
.6% of those patients had previous cardiac surgery; in
articular, 3.2% had previous CABG surgery, with a patent
eft internal thoracic artery–to–left descending coronary ar-
ery graft. The patients had multiple comorbidities (in 80%
f patients, 3 risk factors coexisted; in 55% of patients, 5
oexisted). Seven percent of patients were affected by
hronic renal failure (serum creatinine  150 mg/dL), 10%
ad previous stroke, 17% of patients had diabetes, and 25%
ere affected by chronic lung disease. In 8% the left ven-
ricular function was severely impaired, with an ejection
raction less than 40%. Finally, 2% of patients required
n urgent operation. The operative risk, which was cal-
ulated by EuroSCORE grading,5 was low (EuroSCORE
–2) in 24% of patients and medium (EuroSCORE 3–5)
n 46%. In 30% of patients the operative risk was high
EuroSCORE  6). According to in-hospital morbidity,
ajor neurologic complications (either stroke or transient
schemic attack) occurred in 0.9% of patients, and acute
enal failure and respiratory failure occurred in 0.3% of
atients. In 4% of patients, postoperative bleeding required
surgical revision, and perioperative acute myocardial in-
arction was observed in 0.6%. Overall in-hospital mortality
as 0.3%, whereas the expected mortality (according to a
ean EuroSCORE of 4.3) was 3%. Among this population,
ome challenging situations were encountered: severe cal-
ifications of the ascending aorta were observed in 7 pa-
ients and an intraoperative conversion of the surgical strat-
gy to a Bentall operation was necessary in 3 of them. Three
atients with a porcelain aorta were scheduled to undergo
picoaortic bypass surgery instead of traditional AVR.
Sixty-nine percent of patients received a biologic pros-
hesis, whereas in 31% a mechanical valve was implanted.
ean follow-up time was 16  11 months. Kaplan–Meier
urvival was 92%  0.03% at 40 months.
In view of the results of percutaneous AVR, the opti-
ism expressed is premature. In fact, the only publishederies (6 patients affected by end-stage aortic stenosis), a
The Journal of Thoracicresented by Cribier and associates,6 evidenced some major
rawbacks, such as perivalvular leakage, which is caused by
he persistence of empty space between the percutaneous
nd native valves owing to calcifications and which was
bserved in the majority of patients. Moreover, coronary
ow obstruction provoked by the valved stent and athero-
mbolism of calcific debris during the positioning of the
evice are possible. Grube and colleagues4 have recently
escribed 1 single case of implantation of a self-expandable
alve prosthesis by the retrograde approach, which was
eemed to facilitate coaxial positioning and to reduce the
isk of perivalvular leakage, but required extracorporeal
irculatory support (ECC) as a “safety measure.” In fact,
ome intraprocedural complications, such as ejection of the
alve into the ascending aorta at the time of balloon infla-
ion or hemodynamic collapse after balloon predilation,
ave been reported.6 Finally, several technical difficulties
ave been described for both the antegrade and retrograde
pproach,4 so that a transapical access through a median
ternotomy has been hypothesized. However, we are con-
erned that a percutaneous AVR that necessitates either a
edian sternotomy or ECC no longer sounds like percuta-
eous AVR.
The technique has been defined by several authors as
attractive” and “promising,” being able in the near future to
ust aortic valve surgery. However, we believe that the
videnced limits make it not so attractive and that this
pproach is not so promising, especially for insufficient
ortic valves, which might not be suitable at all for percu-
aneous replacement. In fact, in the vast majority of cases,
he insufficiency is due to a degenerative disease that usu-
lly involves the entire aortic root, with subsequent dilation
nd an increased risk for potential perivalvular leakage.
esides, an unacceptable risk of coronary flow obstruction
ight be the consequence of the pathophysiologic expan-
ion of the left ventricular outflow tract characterizing aortic
nsufficiency.3
Before being accepted, transcatheter valve replacement
eeds to prove its effectiveness when compared with surgi-
al valve replacement, which is and remains the gold
tandard.
The first human report of percutaneous AVR by Cribier
nd colleagues7 dates back to 2002 and described a single
atient who died 17 weeks after the implant of complica-
ions related to peripheral artery disease. More recently, the
ame group6 reported their overall clinical experience:
mong 11 patients with end-stage aortic stenosis, they en-
ountered intraprocedural technical failures in 2 (18%)
atients and a high short-term mortality resulting from comor-
idities (4 patients). At a very short follow-up time (18 days-
.5 months), there were no signs of heart failure in the remain-
ng 6 patients. Grube and coworkers4 have recently proposed
n antegrade transseptal implantation, supported by ECC, of a
and Cardiovascular Surgery ● Volume 133, Number 2 295
sF
c
p
b
g
t
s
o
a
b
e
c
t
p
h
b
s
o
v
n
a
f
f
g
t
s
i
s
t
r
s
d
h
E
s
a
s
p
e
a
d
m
p
r
o
c
t
c
m
i
i
r
p
s
e
y
m
m
p
t
n
s
a
n
c
l
b
c
e
h
o
t
a
d
C
c
f
c
m
e
a
t
Editorials di Marco and Gerosa
2
ED
ITO
RIA
Lelf-expandable CoreValve aortic valve (CoreValve SA, Paris,
rance). They reported a 2-week follow-up with no compli-
ations, specifying that the only patient treated (who was
resumably too impaired to withstand a surgical AVR) will
e followed up during the next 5 years. Their intentions are
ood, but probably not realistic. Furthermore, we believe
hat any surgical report with a 2-week follow-up can rea-
onably be judged inadequate.
What about the guarantees of functioning and durability
ffered by valved stents? Cribier and associates7 developed
n original percutaneous valve initially composed of three
ovine pericardial leaflets mounted within a balloon-
xpandable stent; the valve had passed 2 million cycles,
orresponding to 2½ years. In their most recent experience,
hey6 adopted a newly designed valve formed by equine
ericardial leaflets mounted within a reinforced stent that
ad completed 200 million cycles. Before clinical implant,
oth valves were tested in animal models. However, we
hare the concerns of Fish3 about the possible unsuitability
f animal models for preclinical evaluation of percutaneous
alves, inasmuch as the results are strictly dependent on the
ative valve status. We strongly believe that current Food
nd Drug Administration requirements need an adjustment
or percutaneous devices in consideration of the specific
eatures of both the devices and the procedural methods.
Percutaneous treatment currently does not offer adequate
uarantees inasmuch as the preclinical evaluation is poten-
ially inadequate and the clinical experience is poorly sub-
tantiated by short-term results. By contrast, the limits of
nterventional approaches appear clear8 and mainly repre-
ented by the following issues:
● Current approaches and delivery routes are unsatis-
factory: currently, both antegrade and retrograde ap-
proaches have been proposed, but none appear to be
free from disadvantages.
● Optimal positioning of the stent to avoid coronary
ostial impairment and paravalvular leakage is still a
challenge.
The need for an optimal approach is evidenced also by
he recent attempts to perform hybrid procedures,9 which
equire a ministernotomy or epigastric incision to deliver a
utureless valve through the cardiac apex. The technical
ifficulties in the optimal positioning of the valved stent
ave been overcome by some authors with the support of
CC,4 which partially negates the utility of a nonsurgical
trategy. The possible jeopardizing of coronary flow is still
major challenge in insufficient aortic valves owing to the
pecific pathophysiologic anatomic modifications.3 Finally,
aravalvular leakage was evident in 5 of 6 patients in the
xperience reported by Cribier and colleagues6 (mild in 3
nd severe in 2 patients); the risk of compromising hemo-
ynamics results in severely ill patients. o
96 The Journal of Thoracic and Cardiovascular Surgery ● FebrFinally, we must be aware that cardiac surgeons themselves
ight contribute to the currently inappropriate spreading of
ercutaneous techniques. In fact, the analysis of a nationally
epresentative database2 has outlined that a significant portion
f patients affected by severe aortic stenosis are not even
onsidered for aortic valve surgery. In fact, they are considered
o be at prohibitive operative risk because of either significant
omorbidities or advanced age. We should consider this infor-
ation as an alert, because this cohort of patients might be
nappropriately labeled as inoperable and arbitrarily referred to
nterventional cardiologists for a percutaneous approach. In a
ecent series published by Gammie and collegues,10 among 14
atients undergoing aortic valve bypass surgery as alternative
urgery for aortic stenosis, 50% of patients had been initially
xcluded from surgery in other centers. The question is, 10
ears ago these patients would have been treated with the sole
edical therapy, but what about now? How many of those
ight be referred for percutaneous AVR as inappropriate com-
assionate therapy?
We believe that the factors that in the past were tradi-
ionally considered as contraindications for cardiac surgery
o longer contraindicate AVR; instead, they must be con-
idered as factors that make the operation more challenging
nd require tailored surgical strategies. Mainly, four issues
eed to be deepened:
1. Reduced life expectancy owing to either advanced
age or significant commorbidities
2. Presence of heavy calcifications of the ascending
aorta, known as porcelain aorta
3. Previous CABG with patent grafts
4. Pathologic conditions that contraindicate cardiopul-
monary bypass
Regarding reduced life expectancy, the old paradigm that
onsidered AVR worthwhile only in those patients whose
ife expectancy was equal or superior to the expected dura-
ility of the prosthesis implanted has been overcome. As a
onsequence of continuous improvements in both intraop-
rative and postoperative care, operative mortality rates
ave been lowered to 0.3% for isolated AVR, as shown by
ur experience. The very low perioperative risk along with
he widely known unfavorable natural history of severe
ortic stenosis contributed to the extension of surgical in-
ications to octogenarian and even nonagenarian patients.
urrently, advanced age cannot be considered an exclusion
riterion for AVR, and nonagenarian patients have success-
ully undergone valve surgery.11
Porcelain aorta is a rarely encountered condition, being
haracterized by a severely calcified ascending aorta that
akes aortic clamping extremely difficult or impossible and
xposes the patient to the risk of neurologic deficits second-
ry to atheroembolization and postoperative aortic dissec-
ion. Deep hypothermic circulatory arrest with replacement
f the ascending aorta has been proposed,12 but simplified
uary 2007
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Lethods such as apicoaortic conduit and endovascular
lamping appear as more appealing alternatives. An api-
oaortic conduit that consists in the interposition of a valved
raft between the apex of the left ventricle and the descend-
ng aorta was first evaluated clinically about 50 years ago13
ut soon was abandoned because of high rates of hemolysis
nd embolization compared with conventional AVR.
The recent introduction of transcatheter approaches, pro-
osed for those patients excluded from surgery because of
orcelain aorta, induced cardiac surgeons to reinterpret the
picoaortic conduit as an alternative to conventional surgery
ble to overcome the limits imposed by a severely calcified
orta. In this view, apicoaortic conduit surgery offers sev-
ral advantages:
● It does not require sternotomy, but can be realized
through a lateral thoracotomy. Minithoracotomy asso-
ciated with thoracoscopy has been also reported. This
is particularly useful in those patients who undergo a
resternotomy and especially in patients with patent cor-
onary artery grafts. Besides, it allows faster recovery.
● No damage to native coronary arteries is possible and
there is no risk of atrioventricular block.
● There is no risk for cerebral atheroembolization.
● Finally, it can be performed without cardiopulmonary
bypass and cardioplegic arrest, with an off-pump
technique.
Concomitant carotid artery disease, chronic renal failure,
epressed left ventricular systolic function, and other co-
orbidities that make the candidate unsuitable for conven-
ional on-pump surgery no longer represent an absolute
ontraindication.
In his series, Gammie and associates10 report excellent
esults of aortic valve bypass surgery in patients otherwise
xcluded from surgery, with neither postoperative stroke
or permanent renal failure. Those patients, accounting for
.8% of all the patients undergoing isolated AVR, were at
igh operative risk because of prior CABG with patent
rafts (12/14 patients), chronic renal failure, severe lung
isease, or cerebrovascular disease.
Last, endovascular aortic clamping has been presented as
 further no-clamping approach. Ooi and colleagues14 de-
eloped aortic cannulation by the Seldinger technique plus
nternal occlusion of the ascending aorta by means of a
oley catheter. The method allows both antegrade admin-
stration of cardioplegia and proximal aortic venting.
In conclusion, we believe that currently there are no factors
hat might preclude surgery for any patient. On the other hand,
e are concerned that a percutaneous approach, which has not
et provided enough guarantees compared with surgical ther-
py, might appear a safer and less demanding alternative both
or the patients and for the referring cardiologists.
Instead of finding a way to replace surgical therapy,
ercutaneous approaches should focus on coming up to the
The Journal of Thoracicide of surgery, to support it in its current limitations. In
act, even if surgical AVR represents the gold standard
herapy for aortic valve disease, the search for the ideal
alve substitute is still ongoing: biologic prostheses are
ssociated with unsatisfactory durability in young patients,
xposing them to the need for repeated reoperations, and
echanical valves necessitate lifelong anticoagulation ther-
py. Besides, both of them are inadequate in patients in
hom a height-weight growth is expected, and neither ho-
ografts nor autografts are satisfying alternatives. We be-
ieve that the application of a percutaneous technique, which
s easily repeatable, might efficaciously join cardiac surgery
n young patients: in these patients the implantation of a
ioprosthesis by surgery might be appealing as a first-line
pproach, since it does not expose the patients to the risks
elated to anticoagulation. Owing to the limited durability of
iologic valves in young patients and the lack of growth
otential of artificial valves, further procedures are likely to
e necessary. We believe that these procedures might be
erformed with a percutaneous technique that could be
epeated over the years. In fact, the presence of a rigid
ioprosthetic stent as well as the absence of calcifications of
he degenerated bioprosthesis reduce the risks of peripros-
hetic leak (which represents a major risk for calcific
tenosis).
This hybrid approach would allow young patients to
each the cutoff age for the definitive surgical implantation
f a second bioprosthesis without exposing them to the risk
f multiple sternotomies.
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